α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity

α-Synuclein aggregation is a key driver of neurodegeneration in Parkinson's disease and related syndromes. Accordingly, obtaining a molecule that targets α-synuclein toxic assemblies with high affinity is a long-pursued objective. Here, we exploit the biophysical properties of toxic oligomers a...

Descripción completa

Detalles Bibliográficos
Autores: Santos Suárez, Jaime|||0000-0001-9045-7765, Gracia González, Pablo, Navarro, Susanna|||0000-0001-8160-9536, Peña Díaz, Samuel|||0000-0002-2902-823X, Pujols Pujol, Jordi|||0000-0001-9424-5866, Cremades, Nunilo|||0000-0002-9138-6687, Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060, Ventura, Salvador|||0000-0002-9652-6351
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:256391
Acceso en línea:https://ddd.uab.cat/record/256391
https://dx.doi.org/urn:doi:10.1038/s41467-021-24039-2
Access Level:acceso abierto
Palabra clave:Peptides
Biophysics
Protein aggregation
Protein design
Descripción
Sumario:α-Synuclein aggregation is a key driver of neurodegeneration in Parkinson's disease and related syndromes. Accordingly, obtaining a molecule that targets α-synuclein toxic assemblies with high affinity is a long-pursued objective. Here, we exploit the biophysical properties of toxic oligomers and amyloid fibrils to identify a family of α-helical peptides that bind to these α-synuclein species with low nanomolar affinity, without interfering with the monomeric functional protein. This activity is translated into a high anti-aggregation potency and the ability to abrogate oligomer-induced cell damage. Using a structure-guided search we identify a human peptide expressed in the brain and the gastrointestinal tract with analogous binding, anti-aggregation, and detoxifying properties. The chemical entities we describe here may represent a therapeutic avenue for the synucleinopathies and are promising tools to assist diagnosis by discriminating between native and toxic α-synuclein species. α-Synuclein (αS) aggregation is a driver of several neurodegenerative disorders. Here, the authors identify a class of peptides that bind toxic αS oligomers and amyloid fibrils but not monomeric functional protein, and prevent further αS aggregation and associated cell damage.